Zimberelimab
- Generic Name
- Zimberelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2259860-24-5
- Unique Ingredient Identifier
- ZBL7O904IL
- Indication
用于治疗二线以上复发或难治性经典型霍奇金淋巴瘤（r/r cHL）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- 🇺🇸
Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04104672
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸UW Health - UW Carbone Cancer Center - Medical Oncology Clinic, Madison, Wisconsin, United States
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04087018
- Locations
- 🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸Christiana Care Health System - Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT03846310
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
🇰🇷Bundang CHA Medical Center, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03629756
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇦🇺Cabrini Health Limited, Malvern, Australia
🇺🇸Scottsdale Healthcare Hospitals dba HonorHealth, Scottsdale, Arizona, United States
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03628677
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Tweed Hospital, Tweed Heads, New South Wales, Australia
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- 🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.